Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07235579Completed

Understanding Cauda Equina Syndrome

Role: collaborator

NCT04995224Recruiting

Mechanism of Chronic Pain in Patients With IBD

Role: collaborator

NCT05412758Not ApplicableRecruiting

Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)

Role: collaborator

NCT06302660Active Not Recruiting

Profiling Microbiome Associated Metabolic Pathways in Oesophageal Cancer Survivors

Role: collaborator

NCT03684564Phase 2Unknown

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

Role: collaborator

NCT04811807Unknown

Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease

Role: collaborator

NCT04419571Completed

Outcomes in Emergency Laparotomies During COVID-19 Pandemic

Role: lead

NCT04375501Completed

A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic

Role: collaborator

All 8 trials loaded